Step 4: The Road Map to CMT Clinical Trials

Step 4: FDA Regulatory

HNF continues to engage with FDA regulators to incorporate innovative and digital technologies to enhance the precision of sensitive data capture. Our pilot studies serve to accelerate, develop, and validate both traditional and innovative methods for CMT functional outcome measures leading to clinical trial approval. We continue to share the groundbreaking CMT Report from our 2018 Patient-focused Drug Development Meeting. Through sharing these findings with the FDA, biotech, and Pharma, we ensure that the patients’ experiences, perspectives, and needs can be used to develop new treatments and support their approval by the (FDA).

HNF will continue down the road to human clinical trials as patients, advocates, researchers, and innovators. Just like CMT has its challenges, so does our journey to treatments. We thank you from the bottom of our hearts for your support in 2023 and continued dedication in 2024 and beyond.
We need your support and donations to continue to fuel our efforts to reach our ultimate finish line: successful human clinical trials for CMT.

The Hereditary Neuropathy Foundation invites you to explore our CMT Roadmap and discover how, together, we're making an impact that matters.

Download our CMT Clinical Trial Road Map & learn more!
https://www.hnf-cure.org/our-impact/c...